Anti-Fungal Treatment Study Updated by NexMed (NEXM)
More News related to NEXM
- Liberty Analytics Co. Initiates Independent Research Coverage on NexMed, Inc.
- NexMed (NEXM) Announces $2.7 Million Cash Infusion
- NexMed Receives over $2.7 Million Cash Infusion
- NexMed Granted Request for Continued Listing on NASDAQ
- Morning Movers 01/20: DEAR, TIBB, LXRX, CTZN, PONE, CREE Higher; VRS, NEXM, AXU, SUPX Lower
More News related to Corporate News
- Alcatel-Lucent (ALU) Selected by AT&T (T) As One of Two Suppliers for LTE Mobile Broadband Technology
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
NexMed, Inc. (Nasdaq: NEXM) today announced that it has completed its post hoc analysis of NM100060, the Company's topically-applied treatment for onychomycosis (nail fungus). NexMed seeks to pursue signing a partner for further development of the product.
NM100060 has previously been tested in approximately 2,000 patients enrolled in three Phase 3 clinical studies conducted by Novartis. On July 7, 2009, the Company announced the mutual decision with Novartis to terminate the exclusive, global licensing agreement for NM100060.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
